Why Aura Biosciences, Inc.’s (AURA) Stock Is Down 5.26%
As of Thursday, November 12, Aura Biosciences, Inc.’s AURA share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Jenna Brashear
Michael Rose
Cynthia McLaughlin
| Share Statistics | AURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $715.0 | $203.5 | 43% |
|
| Shares Out (Mil) | 111.1 | 55.2 | 64% |
|
| Institutional Ownership | 98.4% | 93.3% | 78% |
|
| Float (Mil) | 74.7 | 40.4 | 55% |
|
| Beta | 0.44 | 1.05 | 24% |
|
| Avg Daily Volume (000s) | 765 | 569 | 65% |
|
| Price Change (52-week) |
27.2% | 38.8% | 78% |
|
| Growth | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.8%) | (10.7%) | 11% |
|
| EPS (5yr) | 53.6% | 15.4% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.0% | (15.7%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($137) | ($44) | 9% |
|
| EPS (TTM) | ($1.607) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($109) | ($35) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $-0 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $516 | $142 | 35% |
|
| Valuation | AURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.48 | 1.96 | 65% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (53.5%) | (47.0%) | 10% |
|
| ROE | (61.7%) | (51.8%) | 13% |
|
| Liabilities to Assets | 10.6% | 29.6% | 6% |
|
| F-Score | 4 | 3 | 33% |
|
Aura Biosciences, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors